Immunomodulatory Activity of SGI-110, a 5-aza-2'-deoxycytidine-containing Demethylating Dinucleotide

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2012 Nov 10

PMID 23138873

Citations 32

Authors

Sandra Coral

Giulia Parisi

Hugues J M G Nicolay

Francesca Colizzi

Riccardo Danielli

Elisabetta Fratta

Alessia Covre

Pietro Taverna

Luca Sigalotti

Michele Maio

Affiliations

Soon will be listed here.

Abstract

Purpose: Pharmacologic DNA hypomethylation holds strong promises in cancer immunotherapy due to its immunomodulatory activity on neoplastic cells. Searching for more efficient DNA hypomethylating agents to be utilized to design novel immunotherapeutic strategies in cancer, we investigated the immunomodulatory properties of the new DNA hypomethylating agent SGI-110, that is resistant to in vivo inactivation by cytidine deaminase.

Experimental Design: Cutaneous melanoma, mesothelioma, renal cell carcinoma, and sarcoma cells were treated in vitro with SGI-110. RT-PCR, quantitative RT-PCR, quantitative methylation-specific PCR, and flow cytometric analyses were performed to investigate changes induced by SGI-110 in the constitutive immune profile of cancer cells. The recognition by gp100-specific CTL of gp100-positive melanoma cells, treated or not with SGI-110, was tested by LDH release assays.

Results: SGI-110 induced/up-regulated the expression of investigated cancer/testis antigens (CTA) (i.e., MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A10, GAGE 1-2, GAGE 1-6, NY-ESO-1, and SSX 1-5) in all cancer cell lines studied, both at mRNA and at protein levels. Quantitative methylation-specific PCR analyses identified a hypomethylation of MAGE-A1 and NY-ESO-1 promoters in SGI-110-treated neoplastic cells, demonstrating a direct role of pharmacologic DNA demethylation in CTA induction. SGI-110 also up-regulated the expression of HLA class I antigens and of ICAM-1, resulting in an improved recognition of cancer cells by gp100-specific CTL.

Conclusions: Our findings show that SGI-110 is a highly attractive therapeutic agent to comprehensively increase immunogenicity and immune recognition of neoplastic cells, and provide the scientific rationale for its clinical development to design novel chemo-immunotherapeutic approaches in cancer patients.

Citing Articles

New perspectives on DNA methylation modifications in ocular diseases.

Zong F, Jia D, Huang G, Pan M, Hu H, Song S Int J Ophthalmol. 2025; 18(2):340-350.

PMID: 39967986 PMC: 11754021. DOI: 10.18240/ijo.2025.02.19.

Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies.

Chiec L, Bruno D Int J Mol Sci. 2024; 25(19).

PMID: 39409190 PMC: 11477297. DOI: 10.3390/ijms251910861.

Targeting DNA Methylation Machinery in Pediatric Solid Tumors.

Cristalli C, Scotlandi K Cells. 2024; 13(14.

PMID: 39056791 PMC: 11275080. DOI: 10.3390/cells13141209.

Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream.

Calabro L, Bronte G, Grosso F, Cerbone L, Delmonte A, Nicolini F Front Immunol. 2024; 14:1333661.

PMID: 38259475 PMC: 10800748. DOI: 10.3389/fimmu.2023.1333661.

DNA Methyltransferase 1 Targeting Using Guadecitabine Inhibits Prostate Cancer Growth by an Apoptosis-Independent Pathway.

Karan D, Singh M, Dubey S, Van Veldhuizen P, Saunthararajah Y Cancers (Basel). 2023; 15(10).

PMID: 37345101 PMC: 10216613. DOI: 10.3390/cancers15102763.

References

Coral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E . Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol. 2005; 207(1):58-66. DOI: 10.1002/jcp.20540. View

Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A . Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). J Immunother. 1999; 22(1):16-24. DOI: 10.1097/00002371-199901000-00003. View

Calabro L, Fonsatti E, Altomonte M, Pezzani L, Colizzi F, Nanni P . Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications. J Cell Physiol. 2004; 202(2):474-7. DOI: 10.1002/jcp.20133. View

Weiser T, Ohnmacht G, Guo Z, Fischette M, Chen G, Hong J . Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg. 2001; 71(1):295-301; discussion 301-2. DOI: 10.1016/s0003-4975(00)02421-8. View

Weiser T, Guo Z, Ohnmacht G, Parkhurst M, Marincola F, Fischette M . Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001; 24(2):151-61. DOI: 10.1097/00002371-200103000-00010. View

Coral S, Covre A, Nicolay H, Parisi G, Rizzo A, Colizzi F . Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br J Cancer. 2012; 107(7):1116-24. PMC: 3461156. DOI: 10.1038/bjc.2012.361. View

Fonsatti E, Nicolay H, Sigalotti L, Calabro L, Pezzani L, Colizzi F . Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res. 2007; 13(11):3333-8. DOI: 10.1158/1078-0432.CCR-06-3091. View

Aptsiauri N, Cabrera T, Garcia-Lora A, Lopez-Nevot M, Ruiz-Cabello F, Garrido F . MHC class I antigens and immune surveillance in transformed cells. Int Rev Cytol. 2007; 256:139-89. DOI: 10.1016/S0074-7696(07)56005-5. View

Schrump D, Fischette M, Nguyen D, Zhao M, Li X, Kunst T . Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006; 12(19):5777-85. DOI: 10.1158/1078-0432.CCR-06-0669. View

10.

Weidanz J, Nguyen T, Woodburn T, Neethling F, Chiriva-Internati M, Hildebrand W . Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol. 2006; 177(8):5088-97. DOI: 10.4049/jimmunol.177.8.5088. View

11.

Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F . Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine. Cancer Res. 2004; 64(24):9167-71. DOI: 10.1158/0008-5472.CAN-04-1442. View

12.

Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

13.

Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S . Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993; 53(14):3343-8. View

14.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay H . Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol. 2007; 212(2):330-44. DOI: 10.1002/jcp.21066. View

15.

Yoo C, Jeong S, Egger G, Liang G, Phiasivongsa P, Tang C . Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 2007; 67(13):6400-8. DOI: 10.1158/0008-5472.CAN-07-0251. View

16.

Lebedeva T, Dustin M, Sykulev Y . ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol. 2005; 17(3):251-8. DOI: 10.1016/j.coi.2005.04.008. View

17.

Mutti L, Valle M, Balbi B, Orengo A, Lazzaro A, Alciato P . Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer. 1998; 78(6):740-9. DOI: 10.1002/(sici)1097-0215(19981209)78:6<740::aid-ijc12>3.0.co;2-5. View

18.

Momparler R . Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther. 1985; 30(3):287-99. DOI: 10.1016/0163-7258(85)90053-1. View

19.

Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay H, Danielli R . Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol. 2010; 223(2):352-8. DOI: 10.1002/jcp.22040. View

20.

Chuang J, Warner S, Vollmer D, Vankayalapati H, Redkar S, Bearss D . S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010; 9(5):1443-50. PMC: 2868087. DOI: 10.1158/1535-7163.MCT-09-1048. View